Ginkgo Bioworks Holdings, Inc. (DNA)
NYSE: DNA · Real-Time Price · USD
10.08
+1.34 (15.33%)
At close: Dec 20, 2024, 4:00 PM
10.06
-0.02 (-0.20%)
After-hours: Dec 20, 2024, 7:14 PM EST
Ginkgo Bioworks Holdings Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | 217.95 | 251.46 | 477.71 | 313.84 | 76.66 | 54.18 |
| Revenue Growth (YoY) | -30.81% | -47.36% | 52.21% | 309.40% | 41.48% | - |
| Cost of Revenue | 41.54 | 54.01 | 204.22 | 129.69 | 15.61 | - |
| Gross Profit | 176.41 | 197.45 | 273.49 | 184.15 | 61.05 | 54.18 |
| Selling, General & Admin | 250.24 | 350.66 | 1,403 | 862.95 | 38.31 | 29.48 |
| Research & Development | 464.72 | 580.62 | 1,053 | 1,150 | 159.77 | 96.3 |
| Operating Expenses | 714.97 | 931.28 | 2,456 | 2,013 | 198.07 | 125.78 |
| Operating Income | -538.55 | -733.83 | -2,182 | -1,828 | -137.03 | -71.6 |
| Interest Expense | -0.09 | -0.09 | -0.11 | -2.37 | -2.39 | -2.42 |
| Interest & Investment Income | 44.58 | 57.22 | 20.26 | 0.84 | 2.58 | 5.76 |
| Earnings From Equity Investments | -1.12 | -2.64 | -43.76 | -77.28 | -0.4 | -27.53 |
| Other Non Operating Income (Expenses) | 15.17 | 14.31 | 132.6 | 56.88 | 7.84 | 3.06 |
| EBT Excluding Unusual Items | -480.02 | -665.04 | -2,073 | -1,850 | -129.39 | -92.74 |
| Merger & Restructuring Charges | 76.2 | - | -27.9 | - | - | - |
| Gain (Loss) on Sale of Investments | -26.29 | -54.83 | -53.34 | -11.54 | -3.73 | -27.2 |
| Gain (Loss) on Sale of Assets | -49.52 | -42.5 | 31.89 | - | - | - |
| Asset Writedown | -121.4 | -121.4 | - | - | - | - |
| Other Unusual Items | -2.65 | -9.17 | 1.26 | 23.83 | 8.29 | 0.1 |
| Pretax Income | -651.54 | -892.94 | -2,121 | -1,838 | -124.83 | -119.84 |
| Income Tax Expense | -0.35 | -0.07 | -15.03 | -1.48 | 1.89 | 0.02 |
| Earnings From Continuing Operations | -651.19 | -892.87 | -2,106 | -1,837 | -126.72 | -119.86 |
| Minority Interest in Earnings | - | - | 1.44 | 6.6 | 0.11 | 0.53 |
| Net Income | -651.19 | -892.87 | -2,105 | -1,830 | -126.61 | -119.33 |
| Net Income to Common | -651.19 | -892.87 | -2,105 | -1,830 | -126.61 | -119.33 |
| Shares Outstanding (Basic) | 51 | 49 | 42 | 34 | 32 | 29 |
| Shares Outstanding (Diluted) | 51 | 49 | 42 | 34 | 32 | 29 |
| Shares Change (YoY) | 6.15% | 15.75% | 23.48% | 6.72% | 10.95% | - |
| EPS (Basic) | -12.82 | -18.37 | -50.15 | -53.83 | -3.97 | -4.15 |
| EPS (Diluted) | -12.86 | -18.40 | -50.20 | -55.53 | -4.00 | -4.15 |
| Free Cash Flow | -387.26 | -336.3 | -304.47 | -310.34 | -193.65 | -66.88 |
| Free Cash Flow Per Share | -7.62 | -6.92 | -7.25 | -9.13 | -6.08 | -2.33 |
| Gross Margin | 80.94% | 78.52% | 57.25% | 58.68% | 79.64% | 100.00% |
| Operating Margin | -247.10% | -291.84% | -456.83% | -582.62% | -178.75% | -132.14% |
| Profit Margin | -298.78% | -355.08% | -440.63% | -583.12% | -165.16% | -220.23% |
| Free Cash Flow Margin | -177.68% | -133.74% | -63.74% | -98.89% | -252.62% | -123.43% |
| EBITDA | -477.3 | -662.28 | -2,138 | -1,799 | -123.16 | -60.84 |
| EBITDA Margin | -218.99% | -263.38% | - | - | -160.67% | -112.29% |
| D&A For EBITDA | 61.25 | 71.55 | 44.42 | 29.08 | 13.86 | 10.76 |
| EBIT | -538.55 | -733.83 | -2,182 | -1,828 | -137.03 | -71.6 |
| EBIT Margin | -247.10% | -291.84% | - | - | -178.75% | -132.14% |
| Revenue as Reported | 217.95 | 251.46 | 477.71 | 313.84 | 76.66 | 54.18 |
Source: S&P Capital IQ. Standard template. Financial Sources.